Fig. 2From: Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancerComparison of overall survival in patients with dichotomized according to subgroups in the CHAARTED trial and percentage change in the PSA level at 12 weeks. The low-volume disease in the CHAARTED trial was dichotomized according to the percentage change in the PSA level at 12 weeksBack to article page